From Cheerios box trade dress to generic “googling” to a blockbuster U.S. Supreme Court decision, 2017 was another bumper year for major rulings in trademark law. Here are the 10 you need to remember.
Lawsuit is believed to concern advanced semiconductor manufacturing technologies used for Sony Playstation consoles.
The decision marks a turnaround in policy and follows a deal to cut costs for generic anti-HIV drugs in developing nations.
Endorsement is seen as controversial, since a distribution of generic drugs could violate a variety of patents.
Issue concerns tariffs to license photocopying of books, magazines, newspapers and journals by government staffers.
Seven-year dispute goes back to Dutch supreme court.
Companies are eager to capitalize on a French court ruling that rebuffs the way Google displays advertisements next to results related to trademarked search keywords.
Crocodile Garments agrees to phase out marketing of clothes with crocodile logo in mainland China.
Andrx will receive a license to a patent for the drug from Schering-Plough.
IP litigation rose 18% in 2002, head of China's IPR Office tells news agency.
Agreement with Indian, South African drug makers will cut price of triple-drug regimen by almost one third in developing countries.
Dispute over use of luminescence and fluorescence to analyze compounds being screened for use in the development of new drugs.
In a setback for chewing gum maker, court rules that the combination of "double" and "mint" represents a product description.
Officials discuss experience of the EU-China Intellectual Property Rights Cooperation Program.
Litigation concerned non-incisional permanent birth control procedure.
Suit concerned technology used in test grading.
Judge sees strong indication of confusion of gin brands in trademark suit.
Bill takes aim at imports of pirated films, music and computer software.
Court says Italian electronic group Trucco can formally register "Starix" as an E.U.-wide trademark.
Japan's top drug maker sues Mylan Pharmaceuticals, Watson Pharmaceuticals and Ranbaxy Laboratories over their generic versions of ACTOS (pioglitazone HCl).
Glow Industries had accused Lopez and her partner of infringing its trademark.